KLRS Kalaris Therapeutics, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
05:44
Feb 23
Feb 23
KLRS anti-VEGF durability plus squeeze setup
Author argues KLRS offers asymmetry because TH103 was designed by the inventor of anti-VEGF therapy and Phase 1a showed +10 letter vision gain, ~95% fluid reduction, and 31% needing no retreatment for six months, which could extend dosing intervals in a $13-15B anti-VEGF market. The company trades at roughly $167M market cap with ~$120M cash (EV ~$90M), is funded into Q3 2027 with no forced raise before Phase 1b/2 data, and has ~82% insider ownership, ~28% short float, ~7.6 days to cover, and a ~$5M insider buy post-data. The catalyst is Phase 1b/2 durability data in H2 2026, where if durability holds, supply rather than demand becomes the problem. Main stated risk is that the thesis depends on durability holding in Phase 1b/2.
HIGH
About KLRS Investor Commentary
Across the available history and selected sources, Buzzberg tracks KLRS (Kalaris Therapeutics, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/CobraCodes.